BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of $7.00 per share. BioHarvest expects the gross proceeds from this offering to be approximately $17.4 m
Biotechnology, Pharmaceuticals, Health
2025-11-07 7:30 AM EST | BioHarvest Sciences Inc.
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an update on its pipeline of small molecules for the treatment of retinal diseases. Key third quarter and 2025 year-to-date corporate highlights include: Continued recruitment and patient dosing in KLARITY, an open-label Phase 2 clinical trial evaluating KIO-104 for the treatmen
Biotechnology, Pharmaceuticals
2025-11-07 6:00 AM EST | Kiora Pharmaceuticals, Inc.
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of fiscal year 2026, which ended September 30, 2025. The Company's full financial statements and related MD&A for the first quarter
Biotechnology, Pharmaceuticals
2025-11-06 4:51 PM EST | InMed Pharmaceuticals
BioHarvest Announces Proposed Public Offering of Common Stock
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, BioHarvest also expects to grant the underwriter a 30-day option to purchase up to an additional
Biotechnology, Pharmaceuticals, Health
2025-11-06 4:37 PM EST | BioHarvest Sciences Inc.
Nextleaf Announces Launch of New Recreational Cannabis Brand
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the national launch of its new recreational brand, Yard. Yard is designed for adult-use consumers seeking bold recreational cannabis experiences through high-potency extracts, premium hardware, and flavour-forward formul
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-11-06 9:29 AM EST | Nextleaf Solutions Ltd.
Neural's Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, in which it owns 30.75% int
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-06 8:46 AM EST | Neural Therapeutics Inc.
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025). The presentation generated exceptional interest from both the scientific a
Biotechnology, Pharmaceuticals, Health
2025-11-06 3:15 AM EST | Defence Therapeutics Inc.
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. The Company will host a webcast conference call on Decembe
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-05 7:45 AM EST | Cardiol Therapeutics Inc.
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-04 5:30 PM EST | Medexus Pharmaceuticals Inc.
Rize Oncology Announces Completion of Private Placement and Resignation of Director
Kelowna, British Columbia--(Newsfile Corp. - November 4, 2025) - Rize Oncology Inc. (OTC: RZONF) (the "Company"), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, is pleased to announce that on October 30, 2025 it completed a non-brokered private placement (the "Private Placement") of units of the Company (the "Units"), raising gross proceeds of C$500,000. The Private Placement consisted of the issuance of 5,000,000 Un
2025-11-04 4:27 PM EST | Rize Oncology Inc.
Hemostemix Closes Private Placement of $461,230
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:09 PM EST | Hemostemix Inc.
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the first three patients have been enrolled in the final stage of the Company's pivotal clinical trial of the full implanted Acclaim® cochlear implant. These initial surgeries in this final stage were performed by Dr. Abraham Jacob at the Center for Neurosciences
Biotechnology, Healthcare and Hospitals
2025-11-04 8:00 AM EST | Envoy Medical, Inc.
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an inve
Biotechnology, Pharmaceuticals, Health
2025-11-04 7:30 AM EST | BioHarvest Sciences Inc.
Wellgistics Health Enters into LOI to Acquire Kare Rx Hub
Tampa, Florida--(Newsfile Corp. - November 4, 2025) - We
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-11-04 6:00 AM EST | Wellgistics Health
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from its latest preclinical in vivo study evaluating Accum®-Kadcyla, a novel version of Genentech/Roche's marketed ADC Kadcyla® (ado-trastuzumab
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:15 AM EST | Defence Therapeutics Inc.
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
Rosh Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device develop
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-11-03 4:30 PM EST | IR-MED, Inc.
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 5,663,182 shares of common stock of the Company originally issued in July 2024, December 2024, Januar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 1:40 PM EST | Phio Pharmaceuticals Corp.
CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
- Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile in a heavily pretreated population - - The Company will host a live investor event on December 7, at 8:00 p.m. ET in Orlando following the poster presentation - Cambridge, United Kingdom and Boston, Massachusetts
2025-11-03 9:00 AM EST | CellCentric, Inc
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 7:45 AM EST | Phio Pharmaceuticals Corp.
Britannia Life Sciences Inc. Enters into $11.3 Million Share Exchange Agreement with McEwen Inc. and Britannia Mining Solutions Inc.
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has entered into a share exchange agreement (the "Agreement") with McEwen Inc. ("McEwen") and Britannia Mining Solutions Inc. (doing business as Paragon Geochemical Laboratories Inc.) (together, "Paragon"). Pursuant to the terms of the Agreement, McEwen will acquire 648,002 common shares of Paragon from Britannia at a deemed price
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2025-11-03 7:07 AM EST | Britannia Life Sciences Inc